Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment

Mimi I. Hu, Ilya Glezerman, Sophie Leboulleux, Karl Insogna, Rasim Gucalp, Waldemar Misiorowski, Bennett Yu, Wendy Ying, Rajul K. Jain

Research output: Contribution to journalArticle

27 Scopus citations


Hypercalcemia of malignancy (HCM), caused primarily by tumor-induced bone resorption, may lead to renal failure, coma, and death. Although HCM can be treated with intravenous bisphosphonates, patients may not respond or may relapse on therapy. Denosumab binds the bone resorption mediator RANKL. In this single-arm, open-label, proof-of-concept study, HCM patients with albumin-corrected serum calcium (CSC) levels greater than 12.5 mg/dL (Common Terminology Criteria for Adverse Events grade ≥3) despite recent intravenous bisphosphonate treatment received subcutaneous denosumab on days 1, 8, 15, and 29, and then every 4 weeks. The primary endpoint was the proportion of patients with CSC 11.5 mg/dL or less (grade ≤1) within 10 days of denosumab initiation. In a prespecified interim analysis, 15 patients received denosumab (median CSC = 13.6 mg/dL). Time to response and response duration were analyzed with Kaplan-Meier methods. All statistical tests were two-sided. By day 10, 12 patients (80%; 95% exact confidence interval [CI] = 52% to 96%) responded (CSC ≤11.5 mg/dL); median response duration was 26 days. Ten patients (67%; 95% exact CI = 38% to 88%) had complete responses (CSC ≤10.8 mg/dL) by day 10. Denosumab may offer a new treatment option for HCM.

Original languageEnglish (US)
Pages (from-to)1417-1420
Number of pages4
JournalJournal of the National Cancer Institute
Issue number18
Publication statusPublished - Sep 18 2013


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this